nodes	percent_of_prediction	percent_of_DWPC	metapath
Anileridine—Loperamide—POMC—multiple sclerosis	0.108	0.863	CrCbGaD
Anileridine—OPRM1—IL4-mediated signaling events—IL4R—multiple sclerosis	0.0403	0.0461	CbGpPWpGaD
Anileridine—OPRM1—Peptide GPCRs—CCR1—multiple sclerosis	0.0297	0.034	CbGpPWpGaD
Anileridine—OPRM1—TCR Signaling Pathway—CBLB—multiple sclerosis	0.0269	0.0308	CbGpPWpGaD
Anileridine—OPRM1—G-protein activation—POMC—multiple sclerosis	0.0216	0.0247	CbGpPWpGaD
Anileridine—OPRM1—TCR Signaling Pathway—MALT1—multiple sclerosis	0.0211	0.0241	CbGpPWpGaD
Anileridine—OPRM1—Peptide GPCRs—CXCR3—multiple sclerosis	0.0197	0.0225	CbGpPWpGaD
Anileridine—OPRM1—Peptide GPCRs—CCR2—multiple sclerosis	0.0192	0.0219	CbGpPWpGaD
Anileridine—Pethidine—ALB—multiple sclerosis	0.0172	0.138	CrCbGaD
Anileridine—OPRM1—TCR Signaling Pathway—IL17A—multiple sclerosis	0.0172	0.0196	CbGpPWpGaD
Anileridine—OPRM1—TCR Signaling Pathway—CD28—multiple sclerosis	0.0167	0.0191	CbGpPWpGaD
Anileridine—OPRM1—G alpha (i) signalling events—S1PR1—multiple sclerosis	0.016	0.0183	CbGpPWpGaD
Anileridine—OPRM1—IL4-mediated signaling events—CD40LG—multiple sclerosis	0.0157	0.018	CbGpPWpGaD
Anileridine—OPRM1—IL4-mediated signaling events—IL10—multiple sclerosis	0.0157	0.018	CbGpPWpGaD
Anileridine—OPRM1—IL4-mediated signaling events—IL4—multiple sclerosis	0.0153	0.0175	CbGpPWpGaD
Anileridine—OPRM1—Peptide ligand-binding receptors—CCR1—multiple sclerosis	0.014	0.016	CbGpPWpGaD
Anileridine—OPRM1—Peptide ligand-binding receptors—CXCL13—multiple sclerosis	0.014	0.016	CbGpPWpGaD
Anileridine—OPRM1—G alpha (i) signalling events—RGS1—multiple sclerosis	0.0136	0.0156	CbGpPWpGaD
Anileridine—OPRM1—Class A/1 (Rhodopsin-like receptors)—S1PR1—multiple sclerosis	0.0127	0.0145	CbGpPWpGaD
Anileridine—OPRM1—Peptide GPCRs—CCR5—multiple sclerosis	0.0124	0.0141	CbGpPWpGaD
Anileridine—OPRM1—GPCRs, Class A Rhodopsin-like—GPR65—multiple sclerosis	0.012	0.0137	CbGpPWpGaD
Anileridine—OPRM1—G alpha (i) signalling events—CXCL13—multiple sclerosis	0.0118	0.0135	CbGpPWpGaD
Anileridine—OPRM1—G alpha (i) signalling events—CCR1—multiple sclerosis	0.0118	0.0135	CbGpPWpGaD
Anileridine—OPRM1—TCR Signaling Pathway—CD8A—multiple sclerosis	0.0115	0.0132	CbGpPWpGaD
Anileridine—OPRM1—GPCRs, Class A Rhodopsin-like—CCR1—multiple sclerosis	0.011	0.0125	CbGpPWpGaD
Anileridine—OPRM1—TCR Signaling Pathway—CCR5—multiple sclerosis	0.0106	0.0121	CbGpPWpGaD
Anileridine—OPRM1—TCR Signaling Pathway—FAS—multiple sclerosis	0.0105	0.012	CbGpPWpGaD
Anileridine—OPRM1—Class A/1 (Rhodopsin-like receptors)—GPR65—multiple sclerosis	0.0103	0.0117	CbGpPWpGaD
Anileridine—OPRM1—Peptide ligand-binding receptors—CCL3—multiple sclerosis	0.00997	0.0114	CbGpPWpGaD
Anileridine—OPRM1—GPCR ligand binding—S1PR1—multiple sclerosis	0.00969	0.0111	CbGpPWpGaD
Anileridine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR1—multiple sclerosis	0.00938	0.0107	CbGpPWpGaD
Anileridine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL13—multiple sclerosis	0.00938	0.0107	CbGpPWpGaD
Anileridine—OPRM1—Peptide ligand-binding receptors—CXCR3—multiple sclerosis	0.00927	0.0106	CbGpPWpGaD
Anileridine—OPRM1—Peptide ligand-binding receptors—CCR2—multiple sclerosis	0.00901	0.0103	CbGpPWpGaD
Anileridine—OPRM1—Opioid Signalling—POMC—multiple sclerosis	0.00898	0.0103	CbGpPWpGaD
Anileridine—OPRM1—G alpha (i) signalling events—CXCR3—multiple sclerosis	0.00782	0.00893	CbGpPWpGaD
Anileridine—OPRM1—GPCR ligand binding—GPR65—multiple sclerosis	0.00781	0.00893	CbGpPWpGaD
Anileridine—OPRM1—G alpha (i) signalling events—CCR2—multiple sclerosis	0.0076	0.00869	CbGpPWpGaD
Anileridine—OPRM1—GPCRs, Class A Rhodopsin-like—PTGER4—multiple sclerosis	0.00751	0.00858	CbGpPWpGaD
Anileridine—OPRM1—Peptide ligand-binding receptors—CXCL10—multiple sclerosis	0.00749	0.00856	CbGpPWpGaD
Anileridine—OPRM1—GPCRs, Class A Rhodopsin-like—CXCR3—multiple sclerosis	0.00725	0.00829	CbGpPWpGaD
Anileridine—OPRM1—GPCR ligand binding—CXCL13—multiple sclerosis	0.00715	0.00817	CbGpPWpGaD
Anileridine—OPRM1—GPCR ligand binding—CCR1—multiple sclerosis	0.00715	0.00817	CbGpPWpGaD
Anileridine—OPRM1—GPCRs, Class A Rhodopsin-like—CCR2—multiple sclerosis	0.00706	0.00807	CbGpPWpGaD
Anileridine—OPRM1—G alpha (i) signalling events—CNR1—multiple sclerosis	0.00702	0.00802	CbGpPWpGaD
Anileridine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3—multiple sclerosis	0.00669	0.00764	CbGpPWpGaD
Anileridine—OPRM1—TCR Signaling Pathway—CD4—multiple sclerosis	0.00663	0.00758	CbGpPWpGaD
Anileridine—OPRM1—GPCRs, Class A Rhodopsin-like—CNR1—multiple sclerosis	0.00651	0.00744	CbGpPWpGaD
Anileridine—OPRM1—Peptide ligand-binding receptors—CCL5—multiple sclerosis	0.00645	0.00737	CbGpPWpGaD
Anileridine—OPRM1—Class A/1 (Rhodopsin-like receptors)—PTGER4—multiple sclerosis	0.00644	0.00735	CbGpPWpGaD
Anileridine—OPRM1—G alpha (i) signalling events—CXCL10—multiple sclerosis	0.00632	0.00722	CbGpPWpGaD
Anileridine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCR3—multiple sclerosis	0.00622	0.0071	CbGpPWpGaD
Anileridine—OPRM1—TCR Signaling Pathway—IL1B—multiple sclerosis	0.00613	0.007	CbGpPWpGaD
Anileridine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR2—multiple sclerosis	0.00605	0.00691	CbGpPWpGaD
Anileridine—OPRM1—Peptide ligand-binding receptors—CCR5—multiple sclerosis	0.00581	0.00664	CbGpPWpGaD
Anileridine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CNR1—multiple sclerosis	0.00558	0.00638	CbGpPWpGaD
Anileridine—OPRM1—GPCR downstream signaling—S1PR1—multiple sclerosis	0.00548	0.00626	CbGpPWpGaD
Anileridine—OPRM1—G alpha (i) signalling events—CCL5—multiple sclerosis	0.00544	0.00622	CbGpPWpGaD
Anileridine—OPRM1—GPCR ligand binding—CCL3—multiple sclerosis	0.00509	0.00582	CbGpPWpGaD
Anileridine—OPRM1—Opioid Signalling—MAPK1—multiple sclerosis	0.00508	0.0058	CbGpPWpGaD
Anileridine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	0.00502	0.00574	CbGpPWpGaD
Anileridine—OPRM1—Signaling by GPCR—S1PR1—multiple sclerosis	0.00497	0.00568	CbGpPWpGaD
Anileridine—OPRM1—GPCR ligand binding—PTGER4—multiple sclerosis	0.0049	0.0056	CbGpPWpGaD
Anileridine—OPRM1—G alpha (i) signalling events—CCR5—multiple sclerosis	0.0049	0.0056	CbGpPWpGaD
Anileridine—OPRM1—TCR Signaling Pathway—TGFB1—multiple sclerosis	0.00476	0.00544	CbGpPWpGaD
Anileridine—OPRM1—GPCR ligand binding—CXCR3—multiple sclerosis	0.00473	0.00541	CbGpPWpGaD
Anileridine—OPRM1—TCR Signaling Pathway—MAPK1—multiple sclerosis	0.00467	0.00533	CbGpPWpGaD
Anileridine—OPRM1—GPCR downstream signaling—RGS1—multiple sclerosis	0.00466	0.00532	CbGpPWpGaD
Anileridine—OPRM1—GPCR ligand binding—CCR2—multiple sclerosis	0.0046	0.00526	CbGpPWpGaD
Anileridine—OPRM1—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	0.00455	0.0052	CbGpPWpGaD
Anileridine—OPRM1—Peptide ligand-binding receptors—POMC—multiple sclerosis	0.00454	0.00519	CbGpPWpGaD
Anileridine—OPRM1—Peptide ligand-binding receptors—CCL2—multiple sclerosis	0.00444	0.00508	CbGpPWpGaD
Anileridine—OPRM1—GPCR downstream signaling—GPR65—multiple sclerosis	0.00442	0.00505	CbGpPWpGaD
Anileridine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	0.00432	0.00494	CbGpPWpGaD
Anileridine—OPRM1—GPCR ligand binding—CNR1—multiple sclerosis	0.00425	0.00486	CbGpPWpGaD
Anileridine—OPRM1—Signaling by GPCR—RGS1—multiple sclerosis	0.00423	0.00483	CbGpPWpGaD
Anileridine—OPRM1—GPCR downstream signaling—CXCL13—multiple sclerosis	0.00404	0.00461	CbGpPWpGaD
Anileridine—OPRM1—GPCR downstream signaling—CCR1—multiple sclerosis	0.00404	0.00461	CbGpPWpGaD
Anileridine—OPRM1—Signaling by GPCR—GPR65—multiple sclerosis	0.00401	0.00458	CbGpPWpGaD
Anileridine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	0.0039	0.00445	CbGpPWpGaD
Anileridine—OPRM1—Signaling Pathways—LINGO1—multiple sclerosis	0.00388	0.00443	CbGpPWpGaD
Anileridine—OPRM1—G alpha (i) signalling events—POMC—multiple sclerosis	0.00383	0.00438	CbGpPWpGaD
Anileridine—OPRM1—GPCR ligand binding—CXCL10—multiple sclerosis	0.00383	0.00437	CbGpPWpGaD
Anileridine—OPRM1—Signaling by GPCR—CXCL13—multiple sclerosis	0.00367	0.00419	CbGpPWpGaD
Anileridine—OPRM1—Signaling by GPCR—CCR1—multiple sclerosis	0.00367	0.00419	CbGpPWpGaD
Anileridine—OPRM1—TCR Signaling Pathway—IL6—multiple sclerosis	0.00359	0.0041	CbGpPWpGaD
Anileridine—OPRM1—Signaling Pathways—TAGAP—multiple sclerosis	0.00336	0.00384	CbGpPWpGaD
Anileridine—OPRM1—GPCR ligand binding—CCL5—multiple sclerosis	0.00329	0.00376	CbGpPWpGaD
Anileridine—OPRM1—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.00305	0.00348	CbGpPWpGaD
Anileridine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.00298	0.0034	CbGpPWpGaD
Anileridine—OPRM1—GPCR ligand binding—CCR5—multiple sclerosis	0.00297	0.00339	CbGpPWpGaD
Anileridine—OPRM1—Signaling Pathways—S1PR1—multiple sclerosis	0.00294	0.00336	CbGpPWpGaD
Anileridine—OPRM1—Signaling Pathways—GPC5—multiple sclerosis	0.00286	0.00327	CbGpPWpGaD
Anileridine—OPRM1—GPCR downstream signaling—PTGER4—multiple sclerosis	0.00277	0.00317	CbGpPWpGaD
Anileridine—OPRM1—GPCR downstream signaling—CXCR3—multiple sclerosis	0.00267	0.00306	CbGpPWpGaD
Anileridine—OPRM1—Signaling by GPCR—CCL3—multiple sclerosis	0.00261	0.00299	CbGpPWpGaD
Anileridine—OPRM1—GPCR downstream signaling—CCR2—multiple sclerosis	0.0026	0.00297	CbGpPWpGaD
Anileridine—OPRM1—Signaling by GPCR—PTGER4—multiple sclerosis	0.00252	0.00287	CbGpPWpGaD
Anileridine—OPRM1—Signaling Pathways—RGS1—multiple sclerosis	0.0025	0.00286	CbGpPWpGaD
Anileridine—OPRM1—Signaling by GPCR—CXCR3—multiple sclerosis	0.00243	0.00278	CbGpPWpGaD
Anileridine—OPRM1—GPCR downstream signaling—CNR1—multiple sclerosis	0.0024	0.00274	CbGpPWpGaD
Anileridine—OPRM1—Signaling Pathways—GPR65—multiple sclerosis	0.00237	0.00271	CbGpPWpGaD
Anileridine—OPRM1—Signaling by GPCR—CCR2—multiple sclerosis	0.00236	0.0027	CbGpPWpGaD
Anileridine—OPRM1—GPCR ligand binding—POMC—multiple sclerosis	0.00232	0.00265	CbGpPWpGaD
Anileridine—OPRM1—GPCR ligand binding—CCL2—multiple sclerosis	0.00227	0.00259	CbGpPWpGaD
Anileridine—OPRM1—Signaling by GPCR—CNR1—multiple sclerosis	0.00218	0.00249	CbGpPWpGaD
Anileridine—OPRM1—Signaling Pathways—CCR1—multiple sclerosis	0.00217	0.00248	CbGpPWpGaD
Anileridine—OPRM1—Signaling Pathways—CXCL13—multiple sclerosis	0.00217	0.00248	CbGpPWpGaD
Anileridine—OPRM1—GPCR downstream signaling—CXCL10—multiple sclerosis	0.00216	0.00247	CbGpPWpGaD
Anileridine—OPRM1—Signaling by GPCR—CXCL10—multiple sclerosis	0.00196	0.00224	CbGpPWpGaD
Anileridine—OPRM1—GPCR downstream signaling—CCL5—multiple sclerosis	0.00186	0.00213	CbGpPWpGaD
Anileridine—OPRM1—Signaling by GPCR—CCL5—multiple sclerosis	0.00169	0.00193	CbGpPWpGaD
Anileridine—OPRM1—GPCR downstream signaling—CCR5—multiple sclerosis	0.00168	0.00192	CbGpPWpGaD
Anileridine—OPRM1—GPCR downstream signaling—IL2RA—multiple sclerosis	0.00165	0.00189	CbGpPWpGaD
Anileridine—OPRM1—Signaling Pathways—CCL3—multiple sclerosis	0.00154	0.00176	CbGpPWpGaD
Anileridine—OPRM1—Signaling by GPCR—CCR5—multiple sclerosis	0.00152	0.00174	CbGpPWpGaD
Anileridine—OPRM1—Signaling by GPCR—IL2RA—multiple sclerosis	0.0015	0.00171	CbGpPWpGaD
Anileridine—OPRM1—Signaling Pathways—PTGER4—multiple sclerosis	0.00149	0.0017	CbGpPWpGaD
Anileridine—OPRM1—Signaling Pathways—PGR—multiple sclerosis	0.00146	0.00167	CbGpPWpGaD
Anileridine—OPRM1—Signaling Pathways—CXCR3—multiple sclerosis	0.00143	0.00164	CbGpPWpGaD
Anileridine—OPRM1—Signaling Pathways—CD28—multiple sclerosis	0.00142	0.00162	CbGpPWpGaD
Anileridine—OPRM1—Signaling Pathways—CCR2—multiple sclerosis	0.0014	0.0016	CbGpPWpGaD
Anileridine—OPRM1—GPCR downstream signaling—POMC—multiple sclerosis	0.00131	0.0015	CbGpPWpGaD
Anileridine—OPRM1—Signaling Pathways—CNR1—multiple sclerosis	0.00129	0.00147	CbGpPWpGaD
Anileridine—OPRM1—Signaling by GPCR—POMC—multiple sclerosis	0.00119	0.00136	CbGpPWpGaD
Anileridine—OPRM1—Signaling by GPCR—CCL2—multiple sclerosis	0.00116	0.00133	CbGpPWpGaD
Anileridine—OPRM1—Signaling Pathways—CXCL10—multiple sclerosis	0.00116	0.00133	CbGpPWpGaD
Anileridine—OPRM1—Signaling by GPCR—TYK2—multiple sclerosis	0.00106	0.00121	CbGpPWpGaD
Anileridine—OPRM1—Signaling Pathways—CD86—multiple sclerosis	0.00101	0.00116	CbGpPWpGaD
Anileridine—OPRM1—Signaling Pathways—CCL5—multiple sclerosis	0.000998	0.00114	CbGpPWpGaD
Anileridine—OPRM1—GPCR downstream signaling—IL2—multiple sclerosis	0.000969	0.00111	CbGpPWpGaD
Anileridine—OPRM1—Signaling Pathways—SPP1—multiple sclerosis	0.000925	0.00106	CbGpPWpGaD
Anileridine—OPRM1—Signaling Pathways—CCR5—multiple sclerosis	0.000899	0.00103	CbGpPWpGaD
Anileridine—OPRM1—Signaling Pathways—IL2RA—multiple sclerosis	0.000886	0.00101	CbGpPWpGaD
Anileridine—OPRM1—Signaling by GPCR—IL2—multiple sclerosis	0.00088	0.00101	CbGpPWpGaD
Anileridine—OPRM1—Signaling Pathways—APOE—multiple sclerosis	0.000818	0.000935	CbGpPWpGaD
Anileridine—OPRM1—Signaling Pathways—CD80—multiple sclerosis	0.00074	0.000846	CbGpPWpGaD
Anileridine—OPRM1—Signaling Pathways—POMC—multiple sclerosis	0.000703	0.000803	CbGpPWpGaD
Anileridine—OPRM1—Signaling Pathways—CCL2—multiple sclerosis	0.000688	0.000786	CbGpPWpGaD
Anileridine—OPRM1—Signaling by GPCR—MAPK1—multiple sclerosis	0.000673	0.000769	CbGpPWpGaD
Anileridine—OPRM1—Signaling Pathways—TYK2—multiple sclerosis	0.000625	0.000714	CbGpPWpGaD
Anileridine—OPRM1—Signaling Pathways—IL2—multiple sclerosis	0.00052	0.000594	CbGpPWpGaD
Anileridine—OPRM1—Signaling by GPCR—IL6—multiple sclerosis	0.000517	0.000591	CbGpPWpGaD
Anileridine—OPRM1—Signaling Pathways—MMP9—multiple sclerosis	0.000492	0.000562	CbGpPWpGaD
Anileridine—OPRM1—Signaling Pathways—STAT3—multiple sclerosis	0.000437	0.0005	CbGpPWpGaD
Anileridine—OPRM1—Signaling Pathways—MYC—multiple sclerosis	0.000406	0.000464	CbGpPWpGaD
Anileridine—OPRM1—Signaling Pathways—TGFB1—multiple sclerosis	0.000405	0.000463	CbGpPWpGaD
Anileridine—OPRM1—Signaling Pathways—MAPK1—multiple sclerosis	0.000398	0.000454	CbGpPWpGaD
Anileridine—OPRM1—Signaling Pathways—IL6—multiple sclerosis	0.000305	0.000349	CbGpPWpGaD
